ஷின்ஹான் துணிகர முதலீடு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஷின்ஹான் துணிகர முதலீடு. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஷின்ஹான் துணிகர முதலீடு Today - Breaking & Trending Today

Funding to take Therapies to next Level


Feb 12 2021 Read 707 Times
AffyXell Therapeutics, a joint venture between Avacta Group and Daewoong Pharmaceutical (Seoul) has closed a Series A venture capital investment of $7.3 million to develop genetically modified stem cells that will produce and secrete therapeutic proteins in situ in the patient.
Established in January 2020, AffyXell has combined Avacta’s Affimer platform with Daewoong’s mesenchymal stem cell (lMSC) platform to produce Affimer molecules generated to suppress immune response and restore immune balance.
While initially focusing on inflammatory and autoimmune diseases and prevention of organ transplant rejection, longer term goals could also include applications in regenerative medicine, infectious diseases and oncology. ....

Sengho Jeon , Avacta Affimer , Alastair Smith , Samsung Venture Investment Corporation , Shinhan Investment Corporation , Avacta Group , Affyxell Therapeutics , Daewoong Pharmaceutical , Shinhan Venture Investment , Smilegate Investment , Kolon Investment , Stonebridge Ventures , Gyeongnam Venture , Chief Executive Officer , Cambridge Based Avacta Group , அலெஸ்டர் ஸ்மித் , சாம்சங் துணிகர முதலீடு நிறுவனம் , ஷின்ஹான் முதலீடு நிறுவனம் , ஷின்ஹான் துணிகர முதலீடு , ஸ்‌டநெபிட்ஜ் முயற்சிகள் , தலைமை நிர்வாகி அதிகாரி ,

Avacta Group plc: Avacta announces AffyXell $7.3 Million Series A Financing


Avacta Group plc: Avacta announces AffyXell $7.3 Million Series A Financing
Avacta s next generation cell and gene therapy joint venture with Daewoong Pharmaceutical secures Series A venture funding
Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, is pleased to announce that AffyXell Therapeutics ( AffyXell ), the joint venture with Daewoong Pharmaceutical ( Daewoong ), has closed a Series A venture capital investment of $7.3 million to further develop its pipeline of next generation cell and gene therapies.
AffyXell was established in January 2020 by Avacta and Daewoong as a Joint Venture to develop novel mesenchymal stem cell (MSC) therapies. AffyXell is combining Avacta s Affimer platform with Daewoong s MSC platform such that the stem cells are genetically modified to produce and secrete therapeutic Affimer proteins in situ in the patient. The Affimer proteins are designed to enhance the therapeutic effects of the MSC creating a ....

Avacta Affimer , Sengho Jeon , Katie Odgaard , Alastair Smith , Shinhan Investment Corporation , Samsung Venture Investment Corporation , Avacta Group , Zyme Communications , Daewoong Pharmaceutical , Affyxell Therapeutics , Joint Venture , Shinhan Venture Investment , Smilegate Investment , Kolon Investment , Stonebridge Ventures , Gyeongnam Venture , Chief Executive Officer , அலெஸ்டர் ஸ்மித் , ஷின்ஹான் முதலீடு நிறுவனம் , சாம்சங் துணிகர முதலீடு நிறுவனம் , ஜய்மே தகவல்தொடர்புகள் , கூட்டு துணிகர , ஷின்ஹான் துணிகர முதலீடு , ஸ்‌டநெபிட்ஜ் முயற்சிகள் , தலைமை நிர்வாகி அதிகாரி ,